STOCK TITAN

Savara (SVRA) Stock Price, News & Analysis

SVRA NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
29 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+17.4% close of November 28, 2025
1-year change
+13.2% closing prices, November 18, 2025 to November 18, 2026
1-month change
+6.1% closing prices, October 16, 2026 to November 18, 2026

Company Description

Savara Inc. (Nasdaq: SVRA) is a clinical stage biopharmaceutical company focused on rare respiratory diseases. The company concentrates its resources on developing therapies for serious lung conditions with limited or no approved pharmacologic treatments. According to company disclosures, Savara’s work centers on autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a chronic and debilitating rare lung disease characterized by abnormal surfactant build-up in the alveoli.

The company’s lead program is MOLBREEVI*, described as a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune PAP. MOLBREEVI is an inhaled investigational medicine delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Savara states that its management team has significant experience in rare respiratory diseases and pulmonary medicine, including identifying unmet needs and advancing product candidates toward approval and commercialization.

Business focus and therapeutic area

Savara operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, with a business model centered on the research, clinical development, and potential commercialization of specialty pharmaceuticals for the respiratory system. Public filings and press releases describe Savara as focusing on rare respiratory diseases, with autoimmune PAP as the primary indication targeted by its lead program.

Autoimmune PAP is described in Savara’s communications as a rare lung disease in which surfactant, a mixture of proteins and lipids that lines the alveoli, accumulates abnormally. In healthy lungs, excess surfactant is cleared by alveolar macrophages, which require stimulation by GM-CSF to function properly. In autoimmune PAP, GM-CSF is neutralized by antibodies, impairing macrophage function, leading to impaired gas exchange and symptoms such as shortness of breath, cough, and fatigue. Over time, this can result in serious complications, including lung fibrosis and the potential need for lung transplantation.

MOLBREEVI program and development status

Across multiple company announcements, Savara describes MOLBREEVI as:

  • A non-glycosylated form of recombinant human GM-CSF formulated as an inhaled investigational medicine.
  • Administered via a proprietary investigational eFlow® Nebulizer System optimized by PARI Pharma GmbH for the delivery of MOLBREEVI.
  • In Phase 3 development for the treatment of autoimmune PAP.

Company press releases state that MOLBREEVI has been granted Fast Track and Breakthrough Therapy Designations by the U.S. Food and Drug Administration (FDA), Orphan Drug Designation by both the FDA and the European Medicines Agency (EMA), and Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for autoimmune PAP. Savara has also reported that the European Patent Office (EPO) has issued or intends to grant patents covering the liquid formulation of MOLBREEVI and the drug–device combination of MOLBREEVI delivered via the eFlow® Nebulizer System, with protection described in company communications as extending into the 2040s.

According to recent news, Savara has submitted and resubmitted a Biologics License Application (BLA) to the FDA for MOLBREEVI for the potential treatment of autoimmune PAP and has requested Priority Review. The company has also indicated plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI to regulatory authorities in Europe and the UK.

Drug–device combination and partnerships

Savara’s disclosures highlight the importance of the drug–device combination in its approach. MOLBREEVI is delivered via PARI’s proprietary investigational eFlow® Nebulizer System, which has been optimized specifically for this therapy. Savara and PARI jointly hold a European patent covering the combination of MOLBREEVI and the eFlow® Nebulizer System for aerosolization of the liquid solution. Company statements also note that it is planned for the proprietary eFlow® Nebulizer System to be commercially marketed for use with MOLBREEVI under the proposed trade name Vespera® Nebulizer System following approval.

In the U.S., Savara has announced an exclusive distribution agreement with PANTHERx Rare Pharmacy, described as the exclusive U.S. specialty pharmacy for MOLBREEVI if it is approved. Under this arrangement, PANTHERx would be responsible for dispensing and distribution of MOLBREEVI in the U.S. and for providing rare disease patient and prescriber support services.

Regulatory and intellectual property positioning

Company communications emphasize regulatory designations and intellectual property as key elements of Savara’s strategy. For autoimmune PAP, Savara reports:

  • Fast Track and Breakthrough Therapy Designations by the FDA.
  • Orphan Drug Designation by the FDA and EMA.
  • Innovation Passport and PIM designations by the UK MHRA.
  • European patents related to the liquid formulation of MOLBREEVI and the MOLBREEVI–eFlow® drug–device combination.

These designations and patents, as described by Savara, are intended to support the development and potential commercialization of MOLBREEVI in the U.S. and Europe and to strengthen the long-term protection of the therapy in key markets.

Capital markets and corporate structure

According to SEC filings, Savara’s common stock trades on The Nasdaq Global Select Market under the ticker symbol SVRA. The company has used public equity offerings and a shelf registration statement on Form S-3 to raise capital, including offerings of common stock and pre-funded warrants. In addition, Savara has entered into a royalty funding agreement with funds managed by RTW Investments, LP, under which the purchaser has agreed to pay Savara a specified purchase price upon FDA approval of MOLBREEVI for autoimmune PAP by a defined date, in exchange for a tiered royalty on future U.S. net sales of MOLBREEVI up to a contractually defined maximum payment. The agreement includes covenants related to indebtedness and a buy-back option under certain change-of-control scenarios, as described in the company’s Form 8-K.

Savara also reports participation in healthcare and investor conferences and the use of corporate presentations to communicate its strategy, clinical development plans, and regulatory progress to the investment community.

Clinical and commercial preparation

In its public statements, Savara notes that it is investing in preparing for the potential commercialization of MOLBREEVI, including commercialization infrastructure, supply, and launch preparation activities in the United States and European Union. The company has highlighted analyses from its pivotal IMPALA-2 trial in autoimmune PAP and has indicated that, based on its perspective, there are no approved pharmacologic therapies for autoimmune PAP in the U.S. or Europe. Savara’s stated goal is to bring what it describes as a potential first pharmacologic treatment for autoimmune PAP to market, subject to regulatory review and approval.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. Company disclosures state that MOLBREEVI is not approved in any indication.

Stock Performance

$5.29
+12.08%
+0.57
Last updated: at
+13.2%
Performance 1 year

Savara (SVRA) closed at $4.72 on November 18, 2026. Over the past 12 months, the price has gained 13.2%.

See what a $1,000 investment in SVRA would be worth today

Average down calculator for SVRA

SVRA Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Savara has 10 recent news articles, with the latest published on . Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, earnings. View all SVRA news →

Financial Highlights

Savara reported operating income of -$123.5M in FY2025, and net income was -$118.8M. Diluted earnings per share stood at -$0.53. The company generated -$101.0M in operating cash flow. The current ratio was 11.85, measuring current assets divided by current liabilities.

-$118.8M
Net Income (FY2025)
-$101.0M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
22
November 22, 2026 Regulatory

FDA PDUFA action date

Savara's molgramostim BLA PDUFA action set for 2026-11-22; FDA Priority Review, no safety/efficacy/manufacturing issues cited.
NOV
22
November 22, 2026 Regulatory

FDA PDUFA Date

U.S. FDA PDUFA target action date for Savara's MOLBREEVI BLA for autoimmune PAP; potential approval triggers funding access.
NOV
22
November 22, 2026 Regulatory

FDA PDUFA decision

FDA PDUFA action date for MOLBREEVI BLA (U.S.); decision on 2026-11-22 could enable approval and access to non-dilutive funding.
Q1
2027
Q1 2027 Regulatory

EMA CHMP decision

CHMP review of MOLBREEVI MAA; decision expected in Q1 2027
Q1
2027
Q1 2027 Regulatory

EMA decision

EMA expected decision window (Q1 2027) on Savara's MOLBREEVI marketing authorization application in Europe.
Q1
2027
Q1 2027 Regulatory

EMA decision window

EMA decision window for validated MOLBREEVI MAA; European regulatory outcome expected between Jan 1 and Mar 31, 2027.
JAN
15
January 15, 2028 Corporate

RSUs vest in full

12,500 RSUs vest after two years, subject to continued employment
FEB
10
February 10, 2028 Corporate

RSUs vesting completion

7,500 RSUs vest in full on 2028-02-10; granted 2026-02-10 (inducement award).
APR
14
April 14, 2028 Corporate

RSU vesting

141,000 RSUs granted to 24 hires under 2021 plan, vest in full two years from 2026-04-14; may dilute shares.
FEB
10
February 10, 2030 Corporate

Options full vesting

7,500 options fully vest on 2030-02-10; $5.27 exercise price, 10-year term, quarterly vesting.
AUG
17
August 17, 2030 Corporate

Option Final Vesting

Final quarterly vesting of inducement stock options granted Aug 17, 2026; completion of 4-year vesting schedule for 74,500 option shares.
APR
14
April 14, 2036 Corporate

Option expiration

18,500 stock options granted at $6.07 exercise price; 10-year term expires 2036-04-14.
AUG
17
August 17, 2036 Corporate

Option Expiration Date

10-year expiration of inducement stock options granted Aug 17, 2026 with $5.37 exercise price; 74,500 option shares affected.
MAR
01
March 1, 2041 Regulatory

European patent expiry

European patent No. 4121000 for MOLBREEVI liquid formulation; exclusivity in Europe runs through March 1, 2041.
MAR
01
March 1, 2041 Regulatory

Australian patent expiry

Australian patent No. 62/990,810 for MOLBREEVI liquid formulation; patent protection in Australia extends through March 1, 2041.
MAR
2041
March 2041 Regulatory

Patent protection ends (liquid)

EPO patent for MOLBREEVI liquid formulation provides protection through March 2041 (Europe).
MAR
01
March 1, 2043 Regulatory

Joint patent expiry

Joint European patent (Savara & PARI) for MOLBREEVI drug-device via PARI eFlow®; protection in Europe through March 1, 2043.
MAR
2043
March 2043 Regulatory

Patent protection ends (device)

European patent for MOLBREEVI drug-device via PARI eFlow nebulizer provides protection through March 2043.

Savara has 18 upcoming scheduled events. The next event, "FDA PDUFA action date", is scheduled for November 22, 2026 (in 3 days). Investors can track these dates to stay informed about potential catalysts that may affect the SVRA stock price.

Short Interest History

Last 12 Months

Short interest in Savara (SVRA) currently stands at 32.3 million shares, up 12.3% from the previous reporting period, representing 15.3% of the float. Since November 2025, short interest has increased by 112.8%.

Days to Cover History

Last 12 Months

Days to cover for Savara (SVRA) currently stands at 12.9 days, up 5.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 127%. Across the settlements charted above, it has ranged from 4.8 to 36.3 days.

SVRA Company Profile & Sector Positioning

Savara (SVRA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SVRA often look at related companies in the same sector, including Verastem, Inc. (VSTM), Jade Biosciences, Inc. (JBIO), Vor Biopharma Inc. (VOR), MoonLake Immunotherapeutics (MLTX), and Immatics N.V. (IMTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SVRA's relative position within its industry.

Frequently Asked Questions

The current stock price of Savara (SVRA) is $5.29 as of November 19, 2026.

The market cap of Savara (SVRA) is approximately $1.2B. Learn more about what market capitalization means .

The FY2025 net income of Savara (SVRA) is -$118.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Savara (SVRA) is -$0.53 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Savara (SVRA) is -$101.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Savara (SVRA), current assets divided by current liabilities, was 11.85 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Savara (SVRA) is -$123.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Its work centers on researching, developing, and preparing to potentially commercialize therapies for serious lung conditions, with a primary focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

MOLBREEVI is Savara’s lead program and is described as a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis. It is an inhaled investigational medicine delivered via a proprietary investigational eFlow® Nebulizer System specifically developed for inhalation of MOLBREEVI.

Savara focuses on rare respiratory diseases, with autoimmune pulmonary alveolar proteinosis (autoimmune PAP) as its primary indication. Company materials describe autoimmune PAP as a chronic and debilitating rare lung disease caused by GM-CSF autoantibodies that impair surfactant clearance in the alveoli.

According to Savara’s SEC filings, its common stock is listed on The Nasdaq Global Select Market under the ticker symbol SVRA.

Savara reports that MOLBREEVI has received Fast Track and Breakthrough Therapy Designations from the FDA, Orphan Drug Designation from both the FDA and EMA, and Innovation Passport and Promising Innovative Medicine designations from the UK’s MHRA for the treatment of autoimmune PAP.

Company disclosures state that MOLBREEVI is an investigational medicine and is not approved in any indication. Savara has submitted and resubmitted a Biologics License Application to the FDA for the potential treatment of autoimmune PAP and has requested Priority Review.

MOLBREEVI is administered as an inhaled medicine via a proprietary investigational eFlow® Nebulizer System developed by PARI Pharma GmbH. The nebulizer system has been optimized specifically for the delivery of MOLBREEVI as described in Savara’s announcements.

Savara has announced that the European Patent Office has issued or intends to grant patents covering the liquid formulation of MOLBREEVI and the drug–device combination of MOLBREEVI delivered via the eFlow® Nebulizer System. The company states that these patents provide long-term protection for MOLBREEVI in Europe.

Savara has announced that it selected PANTHERx Rare Pharmacy as the exclusive U.S. specialty pharmacy for MOLBREEVI, subject to approval. Under the agreement, PANTHERx would handle dispensing, distribution, and rare disease support services for MOLBREEVI in the United States.

Savara’s SEC filings and press releases describe the use of public offerings of common stock and pre-funded warrants under a shelf registration statement, as well as a royalty funding agreement with funds managed by RTW Investments, LP. Under that agreement, Savara would receive a purchase price upon FDA approval of MOLBREEVI for autoimmune PAP by a specified date in exchange for a tiered royalty on future U.S. net sales up to a defined maximum payment.